Aspira Women's Health Provides Update on ARPA-H Sprint Program Partnership to Advance Women's Health
Aspira was originally awarded a $10 Million award through ARPA-H's Sprint for Women's Health to support the development of Aspira's ENDOinform test, a non-invasive blood draw-based multi-omics test utilizing protein and microRNA biomarkers, along with patient-specific data, to fuel a powerful, AI-powered algorithm to aid in the diagnosis of endometriosis in patients with symptoms of the disease.
This test, leveraging technology and expertise originally developed by Aspira for ovarian cancer risk assessment diagnostics, promises the potential to non-invasively confirm presence of suspected endometriosis in patients, enabling physicians to identify patients who may benefit from endometriosis-controlling therapeutics currently available.
The original ARPA-H contract was announced on October 24, 2024, and reflected $10 million divided into eight payments. The first two of those milestone payments, for $2 million and $1.5 million, were received on November 29, 2024, and March 28, 2025, respectively, for a total of $ 3.5 million from the ARPA-H program. On June 9, 2025, Aspira received notice from ARPA-H that ARPA-H and the assigned managing contractor, VentureWell, have determined that Aspira had not met the specifications of Milestone 3, and have therefore elected to terminate the ENDOinform development program contract.
Aspira's CEO, Mike Buhle, commented, 'While we are certainly disappointed in ARPA-H's termination notice, we are highly confident that our team fully achieved all specifications requirements in the Milestone 3 scope of work provisions. We achieved these requirements in early May and are well underway in achieving Milestone 4 targeted specifications. We are confident in our quality of work, and even more so in our understanding of the technical requirements to complete the ENDOinform program.'
Buhle further commented, 'Our R&D team has been excited about the progress we have made, as well as the early indications of our potential success with the ENDOinform program overall. We plan to continue development of this critical women's health program with the help and support of our shareholders, our research & collaboration partners, and the ongoing dedication of our highly talented and missional teammates. ENDOinform promises a dramatic improvement in health outcomes and quality of life for millions of women suffering from endometriosis, both in the U.S. and abroad. The program remains targeted for 2026 completion goals. We look forward to continuing our development work to completion. In fact, compliance with the ARPA-H program involved significant time investment for our R&D team, and this may well offer us a material acceleration in the pace of achieving our goals.'
About Aspira Women's Health Inc.
Aspira Women's Health Inc. is dedicated to the discovery, development, and commercialization of noninvasive, AI-powered tests to aid in the diagnosis of gynecologic diseases. OvaWatch® and Ova1Plus® are offered to clinicians as OvaSuiteSM. Together, they provide the only comprehensive portfolio of blood tests to aid in the detection of ovarian cancer risk for the 1.2+ million American women diagnosed with an adnexal mass each year.
OvaWatch provides a negative predictive value of 99% and is used to assess ovarian cancer risk for women where initial clinical assessment indicates the mass is indeterminate or benign, and thus surgery may be premature or unnecessary. Ova1Plus is a reflex process of two FDA-cleared tests, Ova1® and Overa®, to assess the risk of ovarian malignancy in women with an adnexal mass planned for surgery.
Our in-development test pipeline will expand our ovarian cancer portfolio and address the tremendous need for non-invasive diagnostics for endometriosis, a debilitating disease that impacts millions of women worldwide. In ovarian cancer, we intend to combine microRNA and protein biomarkers with patient data to further enhance the sensitivity and specificity of our current tests. In endometriosis, we have developed the first-ever non-invasive test designed to identify endometriomas, one of the most commonly occurring forms of severe endometriosis. Through our ongoing endometriosis development program, we are combining microRNA and protein biomarkers with patient data, with the intent of identifying all endometriosis independent of disease location or severity.
Forward-Looking Statements
This press release contains forward-looking statements, as defined in the Private Securities Litigation Reform Act of 1995. Forward-looking statements involve a number of risks and uncertainties. Such forward-looking statements include statements regarding, among other things, the timing and completion of any products in the development pipeline and other statements that are predictive in nature, and whether the marketing of the OvaSuite portfolio will prove successful. Actual results could differ materially from those discussed due to known and unknown risks, uncertainties, and other factors. These forward-looking statements generally can be identified by the use of words such as 'designed to,' 'expect,' 'plan,' 'anticipate,' 'could,' 'may,' 'intend,' 'will,' 'continue,' 'future,' and other words of similar meaning and the use of future dates. These and additional risks and uncertainties are described more fully in the Company's filings with the Securities and Exchange Commission (SEC), including those factors identified as 'Risk Factors' in our most recent Annual Report on Form 10-K for the fiscal year ended December 31, 2024, and subsequent Quarterly Reports on Form 10-Q. If any of these risks materialize or our assumptions prove incorrect, actual results could differ materially from the results implied by these forward-looking statements. There may be additional risks that Aspira presently does not know, or that Aspira currently believes are immaterial, that could also cause actual results to differ from those contained in the forward-looking statements. In addition, forward-looking statements reflect Aspira's expectations, plans, or forecasts of future events and views as of the date of this press release. Subsequent events and developments may cause the Company's assessments to change. However, while Aspira may elect to update these forward-looking statements at some point in the future, Aspira expressly disclaims any obligation to do so, except as required by law. These forward-looking statements should not be relied upon as representing Aspira's assessments of any date after the date of this press release. Accordingly, undue reliance should not be placed upon the forward-looking statements.
Investor Relations Contact:
[email protected]
SOURCE: Aspira Women's Health
press release
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
9 minutes ago
- Yahoo
Ubiquiti (UI) Sees 5% Decline Over Past Month
Amidst the buoyant broader markets, where the Dow reached an all-time high and major indices like the S&P 500 and Nasdaq faced slight dips, Ubiquiti experienced a price movement of a 4.54% decline over the past month. This movement contrasts somewhat with market trends which posted overall gains. The company's share performance during this period might have been influenced by various factors, although specific events were not detailed to pinpoint a definite cause. While overall market optimism was influenced by prospects of Federal Reserve rate adjustments, broader economic forces and external market developments could have also weighed on Ubiquiti's stock. Be aware that Ubiquiti is showing 1 possible red flag in our investment analysis. We've found 19 US stocks that are forecast to pay a dividend yield of over 6% next year. See the full list for free. Over the past year, Ubiquiti's shares have delivered a total return including dividends of 128.53%, which is impressive. This performance stands out especially when compared to the broader US market's return of 17.4% and the US Communications industry's return of 43.8% during the same one-year timeframe. Ubiquiti's ability to outpace both the market and industry suggests strong investor confidence, driven by significant earnings growth and an effective business strategy. The company's recent earnings announcements have shown marked improvements, with third-quarter net income rising to US$180.44 million from US$76.29 million year-over-year. These figures bolster Ubiquiti's earnings forecasts, even as revenue growth projections of 5.8% annually fall behind the market's 9.3%. Despite these earnings achievements, Ubiquiti's current share price of US$402.80 remains above the consensus analyst price target of US$343.50, indicating a substantial premium that some investors might view with caution. The recent dip in Ubiquiti's share price amidst broader market gains might reflect these valuation concerns and potential adjustments in market expectations. Click here to discover the nuances of Ubiquiti with our detailed analytical financial health report. This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned. Companies discussed in this article include UI. This article was originally published by Simply Wall St. Have feedback on this article? Concerned about the content? with us directly. Alternatively, email editorial-team@ Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
9 minutes ago
- Yahoo
Duolingo (DUOL) Reports US$252 Million Q2 2025 Sales Growth
Duolingo recently announced impressive Q2 2025 earnings growth, with sales reaching $252 million and net income rising to $45 million, significantly up from the previous year. Despite this strong performance, the company's stock price declined 10% over the past month. This downward movement occurred amid a mixed market backdrop, where major indices like the S&P 500 experienced minor fluctuations yet remained close to record highs. The robust financial results from Duolingo did not seem to counterbalance broader market trends or investor apprehensions concerning economic conditions and potential interest rate changes, contributing to the stock's decline. Every company has risks, and we've spotted 1 warning sign for Duolingo you should know about. Find companies with promising cash flow potential yet trading below their fair value. Despite Duolingo's strong Q2 2025 earnings, with sales hitting US$252 million and net income climbing to US$45 million, the recent 10% decline in the stock price highlights investor concerns beyond immediate financial performance. However, over the longer-term, Duolingo shares have surged 241.62% in three years, showcasing resilience and growth potential amidst broader market fluctuations. Additionally, over the past year, Duolingo outperformed the US Consumer Services industry, which returned 18.6% during the same period. This indicates that while short-term share price movement may reflect transitory market apprehensions, the company's long-term prospects remain robust. The recent earnings announcement underlines the potential impact on future revenue and earnings forecasts, particularly if Duolingo continues expanding into international markets like China and broader Asia. With expected annual revenue growth of 23.2% and earnings forecasted to grow 36.63% per year, the company appears well-positioned for sustained performance improvement. The decline in share price presents a contrasting scenario to the analyst consensus price target of US$497.24, which is significantly above the current price of US$326.93, suggesting potential upside if market conditions stabilize. Dive into the specifics of Duolingo here with our thorough balance sheet health report. This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned. Companies discussed in this article include DUOL. This article was originally published by Simply Wall St. Have feedback on this article? Concerned about the content? with us directly. Alternatively, email editorial-team@ Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
9 minutes ago
- Yahoo
It's time to put these three crypto IPOs on your radar after Circle and Bullish's big debuts
It's time to put these three crypto IPOs on your radar after Circle and Bullish's big debuts originally appeared on TheStreet. Whether or not you think crypto is a pivotal technology or generational scam, there's no arguing that there's money to be made off of it. But despite the improbable returns and all-time highs in leading digital assets like Bitcoin and Ethereum, there might arguably be even better money for investors buying companies selling access to the boom. See, there's an old adage about selling pickaxes to gold miners. And arguably, nobody's done it better than Robinhood () and Coinbase () . The two industry leaders spent years in the dumps after their respective 2021 IPOs, but with the years-long recession of trading speculation in the rear view, the two companies have soared. They're up 475% and 62% over the last year. Their performances have created a lot of FOMO among crypto and fintech operators. And thanks to a slew of new pro-crypto policies from the Republican-run U.S. government, and record valuations in digital asset land, there's a new boom of firms seeking out Wall Street. It's already created some of the year's most fantastical rallies. Take USDC creator Circle Technology () for example, it's up over 400% since its IPO. It's not a one-off thing, either: crypto exchange and media firm Bullish BLSH, which IPOed this past week, proved the demand for crypto IPOs is durable; it's nearly doubled from its IPO price. So who should be on your radar next? Here are three to watch out for: Grayscale If not for Grayscale, the largest digital asset manager, we might have been waiting years for Bitcoin and Ethereum ETFs to become reality. The company was a first-mover in bringing crypto to Wall Street through its Grayscale Bitcoin Trust and Grayscale Ethereum Trust. The funds, plus dozens of other products offered by the asset manager, offered spot exposure to the digital assets long before major asset managers paid any mind to the crypto industry. Next on its list, it plans to take itself to Wall Street, capitalizing on the robust drip of management fees from its various crypto products. It manages over $33 billion in assets. In mid-July, it was reported that the firm had confidentially filed for an IPO. Gemini They might not have invented Facebook, but settlement money in hand, the Winklevoss twins have managed to build a billion-dollar business in the burgeoning crypto business. After buying millions in Bitcoin and attempting to bring a 'Winklevoss Bitcoin Fund' to Wall Street over a decade ago, the twins settled for building their own crypto exchange. Today, Gemini has grown to be one of the larger centralized exchanges. As a result, it's seeking to strike while crypto demand is strong. In fact, it was one of the first firms to throw its hat in the ring, in light of the strong performance seen by Circle. Last it raised money from venture capital investors in Nov. 2021, crypto was at all-time highs. Filing confidentially for an IPO, the company would likely seek a valuation around the $7.1 billion it fetched back then. BitGo Crypto custodian BitGo has also joined the chorus of crypto firms seeking a home on Wall Street. It might score big, given the fact that it's already a massive home for crypto assets. BitGo custodies over $100 billion in assets now, making it one of the largest holders of crypto. It provides services directly to exchanges, asset managers, and other businesses. Not just holding and securing coins, but staking them and providing trading, lending, and borrowing services as a prime broker. It's fair to assume that the firm's near-doubling in assets over the last year is an indication it's ready for prime time, but outside of the $1.75 billion valuation it fetched in Aug. 2023, we won't know a whole lot more until the company's confidential IPO becomes public. Are crypto IPOs a safe bet? It's hard to call anything a sure thing these days, particularly with U.S. stock benchmarks and crypto markets at record levels. For those interested in playing the IPOs, there's likely an opportunity to hop in on the ground floor of the new listings, playing the first-day pop and ensuing optimism. Some brokerages, like Robinhood and SoFi, even allow investors to request shares at the IPO price. For longer-term holders, closer examination of the companies' financials will be a must. Most of that information is not public yet, though. To that end, if you're a crypto believer, a bet on these firms might make sense if they're financially strong and growing. But given the nature of this fickle market, that means betting that the crypto market's best days are still ahead. And that's by no means a sure thing. It's time to put these three crypto IPOs on your radar after Circle and Bullish's big debuts first appeared on TheStreet on Aug 16, 2025 This story was originally reported by TheStreet on Aug 16, 2025, where it first appeared. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
